AIGH Capital Management LLC Has $2.70 Million Holdings in Grace Therapeutics, Inc. $GRCE

AIGH Capital Management LLC lessened its holdings in Grace Therapeutics, Inc. (NASDAQ:GRCE) by 19.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 907,217 shares of the company’s stock after selling 221,280 shares during the period. AIGH Capital Management LLC owned about 0.07% of Grace Therapeutics worth $2,699,000 at the end of the most recent quarter.

Separately, Millington Financial Advisors LLC acquired a new stake in shares of Grace Therapeutics in the 2nd quarter valued at approximately $59,000. 6.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on GRCE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Grace Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Grace Therapeutics to a “hold” rating in a report on Friday. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $12.00.

Grace Therapeutics Price Performance

Shares of NASDAQ GRCE opened at $3.82 on Friday. The company has a 50 day simple moving average of $3.41 and a 200 day simple moving average of $3.22. The firm has a market cap of $59.10 million, a PE ratio of -6.16 and a beta of 0.55. Grace Therapeutics, Inc. has a 1 year low of $1.75 and a 1 year high of $3.99.

Grace Therapeutics (NASDAQ:GRCE) last posted its earnings results on Thursday, November 13th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). As a group, research analysts anticipate that Grace Therapeutics, Inc. will post -1.06 earnings per share for the current fiscal year.

Grace Therapeutics Company Profile

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.